Sagent Pharmaceuticals Receives Innovative Technology Designation From Novation for GLYDO® (Lidocaine HCl Jelly USP, 2%)

SCHAUMBURG, Ill., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) announced its GLYDO® (lidocaine HCl jelly USP, 2%) has received Innovative Technology designation from Novation, the leading healthcare services company that serves the more than 100,000 members and affiliates of VHA Inc., UHC, Children's Hospital Association, and Provista. The designation was based on reviews of GLYDO by hospital experts who attended Novation’s Innovative Technology Expo in November. The annual event provides medical technology suppliers the opportunity to demonstrate their product and gain direct feedback from onsite clinical experts and health care providers on the impact their products may have on improving clinical care, safety, or benefits to organization’s care and business models.

GLYDO is a branded prefilled, ready-to-use, topical anesthetic lubricant in a uniquely designed plastic syringe used during surgical and office-based urological procedures. The GLYDO syringe and its novel UroFitTip was developed by urologists specifically for the urology market. GLYDO is individually packaged and sterilized to maintain the integrity of the sterile field. With two disposable sizes (6 mL and 11 mL) GLYDO is prefilled, preassembled and ready to use to aid in providing efficiency, safety and convenience from use through disposal.

As with all products in Sagent's portfolio, GLYDO features Sagent's PreventIV MeasuresSM Packaging and Labeling, designed to help reduce the risk of medication errors.

“We are proud to receive this recognition from Novation’s Innovative Technology program for our efforts to introduce products utilizing new drug delivery systems that can benefit both patients and healthcare providers,” said Allan Oberman, Chief Executive Officer at Sagent.

“Novation is committed to providing the members we serve with leading-edge technologies that deliver new clinical and operational benefits from what is currently available in the market today,” said Debbie Archer, director of procurement and leader of the Innovative Technology program for suppliers. “After reviewing Sagent’s GLYDO at our annual Innovative Expo, the hospital experts who attended agreed the product offers unique and incremental benefit over other products available on the market today, and recommended it for the Innovative Technology designation.

Since 2003, more than 2000 new and innovative products and technologies have been submitted through the Novation Innovative Technology program. Novation works with member-led councils and task forces to identify and review potentially innovative products. If it is determined that a product is innovative, a contract may be awarded outside of Novation's competitive bid cycle.

To learn more about Novation's Innovative Technology program, visit

About GLYDO (lidocaine HCI jelly USP, 2%)

GLYDO (lidocaine HCI jelly USP, 2%) is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation (oral and nasal).

The package insert, available at and, contains the indications, complete side effect profile, and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.

INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605

Source:Sagent Pharmaceuticals, Inc.